Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 14, 2020 - Issue
Submit an article Journal homepage
145
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Development and Validation of UHPLC-MS/MS Assay for Therapeutic Drug Monitoring of High-dose Methotrexate in Children with Acute Lymphoblastic Leukemia

Le-jing Lian1 Department of Pharmacy, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou 325027, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-1517-4869
ORCID Icon,
Bin Lin2 Department of Clinical Pharmacy, Changxing People’s Hospital, Changxing 313100, People’s Republic of China
,
Xiao Cui1 Department of Pharmacy, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou 325027, People’s Republic of China
,
Jie He1 Department of Pharmacy, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou 325027, People’s Republic of China
,
Zhe Wang1 Department of Pharmacy, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou 325027, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-1403-2578
ORCID Icon,
Xiao-dong Lin1 Department of Pharmacy, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou 325027, People’s Republic of China
,
Wei-jian Ye1 Department of Pharmacy, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou 325027, People’s Republic of China
,
Rui-jie Chen1 Department of Pharmacy, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou 325027, People’s Republic of China
&
Wei Sun1 Department of Pharmacy, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou 325027, People’s Republic of ChinaCorrespondence[email protected] [email protected]
 show all
Pages 4835-4843 | Published online: 10 Nov 2020

References

  • AumenteD, BuelgaDS, LukasJC, et al. Garcia, population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. Clin Pharmacokinet. 2006;45(12):1227–1238. doi:10.2165/00003088-200645120-0000717112298
  • ChengDH, LuH, LiuTT, et al. Identification of risk factors in high-dose methotrexate-induced acute kidney injury in childhood acute lymphoblastic leukemia. Chemotherapy. 2018;63(2):101–107. doi:10.1159/00048682329672292
  • PuiCH, RobisonLL, LookAT. Acute lymphoblastic leukaemia. Lancet. 2008;371(9617):1030–1043. doi:10.1016/S0140-6736(08)60457-218358930
  • WallAM, GajjarA, LinkA, et al. Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia. Leukemia. 2000;14(2):221–225. doi:10.1038/sj.leu.240167310673736
  • ChengDH, LuH, ZouXQ. [Correlation study of blood drug concentration and nephrotoxicity on high dose methotrexate therapy in suggestion of diagnosis and treatment of childhood acute lymphoblastic leukemia in the 4th revised edition]. Zhonghua Er Ke Za Zhi. 2017;55(10):771–774. doi:10.3760/cma.j.issn.0578-1310.2017.10.012.Chinese.29050116
  • BautersT, LammensT, BelinP, et al. Delayed elimination of methotrexate by cola beverages in a pediatric acute lymphoblastic leukemia population. Leuk Lymphoma. 2013;54(5):1094–1096. doi:10.3109/10428194.2012.73791823061529
  • TranHX, HerringtonJD. Effect of ceftriaxone and cefepime on high-dose methotrexate clearance. J Oncol Pharm Pract. 2016;22(6):801–805. doi:10.1177/107815521560852426419690
  • GarciaH, LeblondV, GoldwasserF, et al. [Renal toxicity of high-dose methotrexate]. Nephrol Ther. 2018;14(Suppl. 1):S103–S113. doi:10.1016/j.nephro.2018.02.015.French.29606256
  • HowardSC, McCormickJ, PuiCH, et al. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471–1482. doi:10.1634/theoncologist.2015-016427496039
  • SharbafFG, FarhangiH, AssadiF. Prevention of chemotherapy-induced nephrotoxicity in children with cancer. Int J Prev Med. 2017;8:76. doi:10.4103/ijpvm.IJPVM_40_1729114374
  • CerminaraZ, DuffyA, NishiokaJ, et al. A single center retrospective analysis of a protocol for high-dose methotrexate and leucovorin rescue administration. J Oncol Pharm Pract. 2019;25(1):76–84. doi:10.1177/107815521772974428942720
  • CohenIJ, WolffJE. How long can folinic acid rescue be delayed after high-dose methotrexate without toxicity? Pediatr Blood Cancer. 2014;61(1):7–10. doi:10.1002/pbc.2477024038885
  • De MoerlooseB, SuciuS, BertrandY, et al. Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized Phase 3 trial 58951. Blood. 2010;116(1):36–44. doi:10.1182/blood-2009-10-24796520407035
  • JolivetJ, JansenG, PetersGJ, et al. Leucovorin rescue of human cancer and bone marrow cells following edatrexate or methotrexate. Biochem Pharmacol. 1994;47(4):659–665. doi:10.1016/0006-2952(94)90128-77510479
  • AumenteMD, López-SantamaríaJ, Donoso-RengifoMC, et al. Evaluation of the novel methotrexate architect chemiluminescent immunoassay: clinical impact on pharmacokinetic monitoring. Ther Drug Monit. 2017;39(5):492–498. doi:10.1097/FTD.000000000000043428682926
  • MeiS, ZhuL, LiX, et al. UPLC-MS/MS analysis of methotrexate in human plasma and comparison with the fluorescence polarization immunoassay. Anal Sci. 2017;33(6):665–670. doi:10.2116/analsci.33.66528603183
  • BrandsteterováE, SeresováO, MiertusS, et al. HPLC determination of methotrexate and its metabolite in serum. Neoplasma. 1990;37(4):395–403.2234201
  • Al-GhobashyMA, HassanSA, AbdelazizDH, et al. Development and validation of LC-MS/MS assay for the simultaneous determination of methotrexate, 6-mercaptopurine and its active metabolite 6-thioguanine in plasma of children with acute lymphoblastic leukemia: correlation with genetic polymorphism. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1038:88–94. doi:10.1016/j.jchromb.2016.10.035
  • FDA. Guidance for industry, bioanalytical method validation. U.S. Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research. Centre for Veterinary Medicine; 5 2018.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.